BackSilverback Therapeutics Overview

Silverback Therapeutics Receivables

Track Silverback Therapeutics's receivables ($29M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$28.66M
↑ 208.09% YoYΔ $19.36M vs prior year quarter

Peer average

Loading

Silverback Therapeutics Receivables History

Loading

Silverback Therapeutics vs. peers: Receivables Comparison

Loading

Silverback Therapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Silverback Therapeutics (SBTX) FAQ

Silverback Therapeutics (SBTX) currently reports a receivables of $29M as of March 2026. That compares with $9.3M in the prior-year period — up 208.1% year over year. Use the charts on this page to explore Silverback Therapeutics's receivables history and peer comparisons.

Silverback Therapeutics's receivables increased from $9.3M to $29M — a 208.1% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Silverback Therapeutics reported $29M in receivables as of March 2026. That compares with $9.3M in the prior-year period — up 208.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $29M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Silverback Therapeutics, and consider following SBTX for alerts when major investors trade the stock.

Silverback Therapeutics is classified in the Healthcare sector. On receivables, it currently shows $29M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SBTX with unrelated industries.